JP2004525157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525157A5 JP2004525157A5 JP2002577819A JP2002577819A JP2004525157A5 JP 2004525157 A5 JP2004525157 A5 JP 2004525157A5 JP 2002577819 A JP2002577819 A JP 2002577819A JP 2002577819 A JP2002577819 A JP 2002577819A JP 2004525157 A5 JP2004525157 A5 JP 2004525157A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- reverse transcriptase
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 241000725303 Human immunodeficiency virus Species 0.000 claims 11
- -1 pyridyl N-oxide Chemical class 0.000 claims 11
- 239000003443 antiviral agent Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical group C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 6
- 229960000311 ritonavir Drugs 0.000 claims 6
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 6
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 5
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 5
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 4
- NIDRYBLTWYFCFV-UHFFFAOYSA-N calanolide F Natural products C1=CC(C)(C)OC2=C1C(OC(C)C(C)C1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-UHFFFAOYSA-N 0.000 claims 4
- YQXCVAGCMNFUMQ-UHFFFAOYSA-N capravirine Chemical compound C=1C(Cl)=CC(Cl)=CC=1SC1=C(C(C)C)N=C(COC(N)=O)N1CC1=CC=NC=C1 YQXCVAGCMNFUMQ-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 3
- ATCRIOJPQXDFNY-ZETCQYMHSA-N 6-chloro-2-(1-furo[2,3-c]pyridin-5-yl-ethylsulfanyl)-pyrimidin-4-ylamine Chemical compound S([C@@H](C)C=1N=CC=2OC=CC=2C=1)C1=NC(N)=CC(Cl)=N1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 3
- 108010032976 Enfuvirtide Proteins 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims 3
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims 3
- SVSARCCKBMZNMR-UHFFFAOYSA-N [1-[2-[methyl-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethyl]amino]ethyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1CCN(C)CCN1C=CC(=C[NH+]=O)C=C1 SVSARCCKBMZNMR-UHFFFAOYSA-N 0.000 claims 3
- 229960004748 abacavir Drugs 0.000 claims 3
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 3
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- RYMCFYKJDVMSIR-RNFRBKRXSA-N apricitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1S[C@H](CO)OC1 RYMCFYKJDVMSIR-RNFRBKRXSA-N 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 3
- 229960002656 didanosine Drugs 0.000 claims 3
- 229960003804 efavirenz Drugs 0.000 claims 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 3
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims 3
- 229960002062 enfuvirtide Drugs 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229960001627 lamivudine Drugs 0.000 claims 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 229960000689 nevirapine Drugs 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229960000329 ribavirin Drugs 0.000 claims 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 229960001203 stavudine Drugs 0.000 claims 3
- 229960000523 zalcitabine Drugs 0.000 claims 3
- 229960002555 zidovudine Drugs 0.000 claims 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 3
- NIDRYBLTWYFCFV-FMTVUPSXSA-N (+)-calanolide A Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-FMTVUPSXSA-N 0.000 claims 2
- NIDRYBLTWYFCFV-SEDUGSJDSA-N (+)-calanolide b Chemical compound C1=CC(C)(C)OC2=C1C(O[C@H](C)[C@@H](C)[C@H]1O)=C1C1=C2C(CCC)=CC(=O)O1 NIDRYBLTWYFCFV-SEDUGSJDSA-N 0.000 claims 2
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- 229960001830 amprenavir Drugs 0.000 claims 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- MLILORUFDVLTSP-UHFFFAOYSA-N emivirine Chemical compound O=C1NC(=O)N(COCC)C(CC=2C=CC=CC=2)=C1C(C)C MLILORUFDVLTSP-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 229950005339 lobucavir Drugs 0.000 claims 2
- 229960001852 saquinavir Drugs 0.000 claims 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- IOYGCIOOMSKGEY-UHFFFAOYSA-N CC(CN(CC1)C(C)(CC2)CCN2C(c2c(C)ncnc2C)=O)N1C(C(CC1)CCN1S(C1CC1)(=O)=O)c1cccc(F)c1 Chemical compound CC(CN(CC1)C(C)(CC2)CCN2C(c2c(C)ncnc2C)=O)N1C(C(CC1)CCN1S(C1CC1)(=O)=O)c1cccc(F)c1 IOYGCIOOMSKGEY-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C1)N(CC(CC2)CCN2I)CCN1C(*)(CC1)CCN1C(c1c(C)ncnc1C)=O Chemical compound CC(C1)N(CC(CC2)CCN2I)CCN1C(*)(CC1)CCN1C(c1c(C)ncnc1C)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27993801P | 2001-03-29 | 2001-03-29 | |
| PCT/US2002/009491 WO2002079194A1 (en) | 2001-03-29 | 2002-03-27 | Ccr5 antagonists useful for treating aids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007279663A Division JP2008074862A (ja) | 2001-03-29 | 2007-10-26 | Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004525157A JP2004525157A (ja) | 2004-08-19 |
| JP2004525157A5 true JP2004525157A5 (enExample) | 2006-01-05 |
| JP4248251B2 JP4248251B2 (ja) | 2009-04-02 |
Family
ID=23070981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577819A Expired - Fee Related JP4248251B2 (ja) | 2001-03-29 | 2002-03-27 | Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト |
| JP2007279663A Withdrawn JP2008074862A (ja) | 2001-03-29 | 2007-10-26 | Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007279663A Withdrawn JP2008074862A (ja) | 2001-03-29 | 2007-10-26 | Ａｉｄｓの処置に有用なｃｃｒ５アンタゴニスト |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US6720325B2 (enExample) |
| EP (2) | EP1591444B1 (enExample) |
| JP (2) | JP4248251B2 (enExample) |
| KR (1) | KR100613528B1 (enExample) |
| CN (1) | CN100519554C (enExample) |
| AR (1) | AR033452A1 (enExample) |
| AT (2) | ATE466009T1 (enExample) |
| AU (1) | AU2002255947B8 (enExample) |
| BR (1) | BR0208398A (enExample) |
| CA (1) | CA2442227C (enExample) |
| CZ (1) | CZ20032636A3 (enExample) |
| DE (2) | DE60204951T2 (enExample) |
| DK (1) | DK1373256T3 (enExample) |
| ES (2) | ES2342942T3 (enExample) |
| HU (1) | HUP0400349A3 (enExample) |
| IL (1) | IL157551A0 (enExample) |
| MX (1) | MXPA03008853A (enExample) |
| MY (1) | MY128609A (enExample) |
| NO (1) | NO326349B1 (enExample) |
| NZ (1) | NZ527768A (enExample) |
| PE (1) | PE20020996A1 (enExample) |
| PL (1) | PL364560A1 (enExample) |
| PT (1) | PT1373256E (enExample) |
| RU (1) | RU2316553C2 (enExample) |
| SI (1) | SI1373256T1 (enExample) |
| SK (1) | SK287521B6 (enExample) |
| TW (1) | TWI237638B (enExample) |
| WO (1) | WO2002079194A1 (enExample) |
| ZA (1) | ZA200307474B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2342942T3 (es) * | 2001-03-29 | 2010-07-19 | Schering Corporation | Antagonistas de ccr5 utiles para el tratamiento del sida. |
| MXPA03011722A (es) | 2001-07-02 | 2004-03-19 | Aztrazeneca Ab | Derivados de piperidina utiles como moduladores de actividad de quimiocina. |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
| ES2312856T3 (es) * | 2002-12-13 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos heterociclicos como antagonistas de ccr5. |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| JP4757802B2 (ja) | 2003-11-03 | 2011-08-24 | シェーリング コーポレイション | ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体 |
| JP2007520556A (ja) * | 2004-02-05 | 2007-07-26 | シェーリング コーポレイション | Ｃｃｒ３アンタゴニストとして有用なピペリジン誘導体 |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| ES2431524T3 (es) * | 2004-04-13 | 2013-11-26 | Incyte Corporation | Derivados de piperazinilpiperidina como antagonistas de los receptores de quimiocinas |
| WO2006030925A1 (ja) * | 2004-09-13 | 2006-03-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| MX2007008281A (es) * | 2005-01-06 | 2007-09-07 | Schering Corp | Preparacion de sales farmaceuticas de compuestos de piperazina. |
| DE602006017507D1 (de) * | 2005-01-06 | 2010-11-25 | Schering Corp | Synthese von ccr5 rezeptor antagonisten |
| CN101133050A (zh) | 2005-02-23 | 2008-02-27 | 先灵公司 | 用作趋化因子受体抑制剂的哌啶基哌啶 |
| EP1858887A1 (en) * | 2005-02-23 | 2007-11-28 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| JP2009501793A (ja) | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | 新規ピペリジン誘導体 |
| US7462485B2 (en) * | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| TW200745087A (en) * | 2006-02-24 | 2007-12-16 | Schering Corp | CCR5 antagonists useful for treating HIV |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| US20100063280A1 (en) * | 2006-12-22 | 2010-03-11 | Schering Corporation | Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds |
| WO2009111218A2 (en) * | 2008-02-29 | 2009-09-11 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| AU6135294A (en) | 1993-02-12 | 1994-08-29 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| AU6253996A (en) | 1995-06-07 | 1996-12-30 | Kimberly-Clark Worldwide, Inc. | Inhibition of exoprotein in absorbent article |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| KR100439357B1 (ko) * | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체 |
| IL145741A0 (en) | 1999-05-04 | 2002-07-25 | Schering Corp | Piperazine derivatives useful as ccrs antagonists |
| ES2342942T3 (es) * | 2001-03-29 | 2010-07-19 | Schering Corporation | Antagonistas de ccr5 utiles para el tratamiento del sida. |
-
2002
- 2002-03-27 ES ES05009882T patent/ES2342942T3/es not_active Expired - Lifetime
- 2002-03-27 AR ARP020101142A patent/AR033452A1/es unknown
- 2002-03-27 EP EP05009882A patent/EP1591444B1/en not_active Expired - Lifetime
- 2002-03-27 CZ CZ20032636A patent/CZ20032636A3/cs unknown
- 2002-03-27 BR BR0208398-1A patent/BR0208398A/pt not_active IP Right Cessation
- 2002-03-27 AU AU2002255947A patent/AU2002255947B8/en not_active Ceased
- 2002-03-27 DE DE60204951T patent/DE60204951T2/de not_active Expired - Lifetime
- 2002-03-27 NZ NZ527768A patent/NZ527768A/en unknown
- 2002-03-27 WO PCT/US2002/009491 patent/WO2002079194A1/en not_active Ceased
- 2002-03-27 CN CNB028076540A patent/CN100519554C/zh not_active Expired - Fee Related
- 2002-03-27 DE DE60236218T patent/DE60236218D1/de not_active Expired - Lifetime
- 2002-03-27 PT PT02725381T patent/PT1373256E/pt unknown
- 2002-03-27 CA CA002442227A patent/CA2442227C/en not_active Expired - Fee Related
- 2002-03-27 KR KR1020037012565A patent/KR100613528B1/ko not_active Expired - Fee Related
- 2002-03-27 JP JP2002577819A patent/JP4248251B2/ja not_active Expired - Fee Related
- 2002-03-27 RU RU2003131879/04A patent/RU2316553C2/ru not_active IP Right Cessation
- 2002-03-27 HU HU0400349A patent/HUP0400349A3/hu unknown
- 2002-03-27 MX MXPA03008853A patent/MXPA03008853A/es active IP Right Grant
- 2002-03-27 SI SI200230169T patent/SI1373256T1/sl unknown
- 2002-03-27 ES ES02725381T patent/ES2242856T3/es not_active Expired - Lifetime
- 2002-03-27 IL IL15755102A patent/IL157551A0/xx not_active IP Right Cessation
- 2002-03-27 EP EP02725381A patent/EP1373256B1/en not_active Expired - Lifetime
- 2002-03-27 US US10/107,940 patent/US6720325B2/en not_active Expired - Lifetime
- 2002-03-27 PE PE2002000251A patent/PE20020996A1/es not_active Application Discontinuation
- 2002-03-27 SK SK1196-2003A patent/SK287521B6/sk not_active IP Right Cessation
- 2002-03-27 DK DK02725381T patent/DK1373256T3/da active
- 2002-03-27 AT AT05009882T patent/ATE466009T1/de not_active IP Right Cessation
- 2002-03-27 PL PL02364560A patent/PL364560A1/xx not_active IP Right Cessation
- 2002-03-27 AT AT02725381T patent/ATE299139T1/de active
- 2002-03-28 TW TW091106166A patent/TWI237638B/zh active
- 2002-03-28 MY MYPI20021140A patent/MY128609A/en unknown
-
2003
- 2003-09-25 ZA ZA200307474A patent/ZA200307474B/en unknown
- 2003-09-26 NO NO20034311A patent/NO326349B1/no not_active IP Right Cessation
-
2004
- 2004-02-06 US US10/773,521 patent/US6900211B2/en not_active Expired - Fee Related
- 2004-10-21 US US10/970,216 patent/US7008946B2/en not_active Expired - Fee Related
-
2005
- 2005-02-17 US US11/059,785 patent/US7060701B2/en not_active Expired - Fee Related
- 2005-10-14 US US11/250,247 patent/US7098213B2/en not_active Expired - Fee Related
-
2007
- 2007-10-26 JP JP2007279663A patent/JP2008074862A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525157A5 (enExample) | ||
| JP2002543186A5 (enExample) | ||
| RU2005120376A (ru) | Фармацевтическая композиция для лечения инфекций вирусом иммунодефицита человека, способ лечения на ее основе и набор | |
| EP3707138B1 (en) | Isofuranone compounds useful as hpk1 inhibitors | |
| KR100613528B1 (ko) | Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트 | |
| JP6212765B2 (ja) | 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤 | |
| US10786492B2 (en) | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | |
| RU2001132632A (ru) | Производные пиперазина, применимые в качестве антагонистов CCR5 | |
| US20140357636A1 (en) | Treatment of Skeletal-Related Disorders | |
| CN109153640A (zh) | 用抗病毒剂消除乙型肝炎病毒 | |
| KR101853596B1 (ko) | Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| JP2012501312A5 (enExample) | ||
| RU2006120956A (ru) | Пирроло{2, 3-d}пиримидиновые соединения для лечения отторжения трансплантата | |
| TW201936585A (zh) | 5-氟尿嘧啶化合物 | |
| WO2006121767A2 (en) | 4-aminoquinoline compounds for treating virus-related conditions | |
| US9399639B2 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | |
| EP3219329A1 (en) | Combinations of copanlisib | |
| JP2025503422A (ja) | Ｐｄ－ｌ１を標的とするための方法及び組成物 | |
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| US20210355104A1 (en) | Adenosine receptor binding compounds | |
| JP2006515851A5 (enExample) | ||
| JP2007510653A5 (enExample) | ||
| US11185549B2 (en) | Combination of a PI3K-inhibitor with an androgen receptor antagonist | |
| AU2011202950B2 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |